Home›Stock Screener›Shukra Pharmaceuticals

Shukra Pharmaceuticals Share Price Today | Stock Price & Shukra Pharmaceuticals Share Screener

SHUKRAPHAR Pharmaceuticals & Biotechnology
Live Share Price NSE
₹82.20
▼ -0.05 (-0.06%)
2026-11-18 00:00:00
Live Share Price BSE
₹82.23
▼ -0.02 (-0.02%)
2026-11-18 00:00:00

As of November 18, 2026, the live Shukra Pharmaceuticals share price (NSE: SHUKRAPHAR) is ₹82.20 on NSE and ₹82.23 on BSE, down 0.06% from the previous close, with shares trading between ₹82.16 and ₹83.39 in today's trading session, and a 52-week range of ₹41.42–₹82.25. Track Shukra Pharmaceuticals marketcap in USD to gauge the company's total market size. Use the Shukra Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Shukra Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹7 and net income of ₹-2, with EBITDA of ₹2, an operating margin of 11.0% and a profit margin of -28.6%.

Shukra Pharmaceuticals Market Cap ₹3,614.95 Cr.
SHUKRAPHAR P/E Ratio (TTM) 82.20
Shukra Pharmaceuticals P/B Ratio 29.16
EPS (TTM) ₹0.50
Dividend Yield 0.01%
Debt to Equity 0.06
SHUKRAPHAR 52 Week High ₹82.25
Shukra Pharmaceuticals 52 Week Low ₹41.42
Operating Margin 11.00%
Profit Margin -28.57%
SHUKRAPHAR Revenue (TTM) ₹7.00
EBITDA ₹2.00
Net Income ₹-2.00
Total Assets ₹117.00
Total Equity ₹90.00

Shukra Pharmaceuticals Share Price Chart

Track the current stock price of Shukra Pharmaceuticals with an interactive chart. Analyse SHUKRAPHAR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Shukra Pharmaceuticals stock quote in one place.

The quote of ₹82.20 sits between the 52-week low of ₹41.42 and the 52-week high of ₹82.25, and the latest session moved -0.06% from the previous close.

Shukra Pharmaceuticals Company Profile - Fundamental Screener

Screen Shukra Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SHUKRAPHAR shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE551C01044.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE551C01044

Shukra Pharmaceuticals Balance Sheet Screener

Screen SHUKRAPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹117, up from ₹87 in 2025.

Latest statistics put total assets at ₹117 and shareholder funds at ₹90, with a leverage ratio of 0.06.

Item 2026 2025

Assets

Total Assets 117 87
Current Assets 0 0
Fixed Assets 22 19

Liabilities

Total Liabilities 0 0
Current Liabilities 5 7
Non-Current Liabilities 0 0

Shareholders' Equity

Total Equity 90 63
Share Capital 44 44
Reserves & Surplus 41 19

Shukra Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Shukra Pharmaceuticals income statement and profit fundamentals. Analyze SHUKRAPHAR quarterly results. Shukra Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹7 and net profit was ₹-2, equal to earnings per unit of ₹-0.04, at an operating margin of 11%.

In that period expenses were ₹6, interest cost ₹0 and tax ₹2. The next period listed, 2026-Jun, shows revenue of ₹24 and net profit of ₹13.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Dec

Revenue and Expenses

Revenue 7 24 45 15 7 8 40 12
Expenses 6 4 26 6 4 6 12 7

Operating Costs and Margins

EBITDA 2 20 19 9 2 1 28 5
Operating Profit % 11.00% 81.00% 42.00% 55.00% 24.00% -7.00% 69.00% 37.00%
Depreciation 1 1 1 1 1 1 1 1
Interest 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 0 18 18 8 1 0 27 4
Tax 2 5 5 2 0 -2 7 1
Net Profit -2 13 13 5 1 2 20 3
EPS -0.04 0.30 0.29 0.12 0.02 0.05 0.47 0.72

Shukra Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen SHUKRAPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹3, and net cash flow was an outflow of ₹6.

Over the same period, investing activities used ₹14 and financing activities provided ₹5.

Item 2026-March 2025-March

Cash from Operations and Investing

Operating Activities 3 8
Investing Activities -14 -1

Financing and Net Cash

Financing Activities 5 -5
Net Cash Flow -6 2

Shukra Pharmaceuticals Shareholding Pattern Screener

See Shukra Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Shukra Pharmaceuticals promoter holding and ownership changes for SHUKRAPHAR on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 50.96%, foreign institutions 0.00%, domestic institutions 0.11% and the public 9.37%, spread across 27,173 shareholders.

The shareholder count was 27,173 in 2026-Mar, compared with 28,384 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Aug 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec

Promoter Holding

Promoter Holding 50.96% 50.96% 51.15% 51.15% 50.96% 50.96% 50.96% 50.96%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.44% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.11% 0.11% 0.11% 0.22% 0.11% 0.11% 0.11% 0.11%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 9.37% 9.38% 9.34% 9.65% 9.29% 28.69% 9.20% 9.43%
Other Holding 39.56% 39.55% 39.39% 38.55% 39.64% 20.24% 39.72% 39.50%
Shareholder Count 27,173 28,384 28,384 35,007 18,231 20,337 21,441 25,649

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Shukra Pharmaceuticals. Shukra Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.01 per unit for 2026-March, a yield of 0.01%, compared with ₹0.01 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.01, ₹0.01 and ₹1.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.01 0.01%
2025-March ₹0.01 0.03%
2024-March ₹1.00 4.58%
2023-March ₹0.50 6.13%
2022-March ₹0.50 42.74%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.50 208.33%
2018-March ₹0.50 263.16%
2017-March ₹0.50 156.25%

Shukra Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Shukra Pharmaceuticals stock. Check SHUKRAPHAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Shukra Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Shukra Pharmaceuticals Market Events Screener - Corporate Actions

Get Shukra Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Shukra Pharmaceuticals stock events that may affect SHUKRAPHAR share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Annual General Meeting dated September 28, 2026 and Annual General Meeting dated September 22, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Quarterly Result Announcement NA 16.60%
2026-09-28 2026-09-28 Annual General Meeting NA 26.66%
2026-09-22 2026-09-22 Annual General Meeting NA 6.37%
2026-09-21 2026-09-21 Dividend ₹ 0.01 /share 66.36%
2026-08-12 2026-08-12 Quarterly Result Announcement NA 23.79%
2026-07-06 2026-07-06 Extraordinary General Meeting NA 2.92%
2026-05-07 2026-05-07 Quarterly Result Announcement NA 13.62%
2026-02-04 2026-02-04 Quarterly Result Announcement NA -7.11%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -0.17%
2025-11-01 2025-11-01 Extraordinary General Meeting NA 19.04%
2025-09-30 2025-09-30 Annual General Meeting NA 34.10%
2025-09-18 2025-09-18 Dividend ₹ 0.01 /share 126.55%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -9.76%
2025-05-29 2025-05-29 Quarterly Result Announcement NA -5.08%
2025-03-21 2025-03-21 Split 1:10 5.12%

Shukra Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen SHUKRAPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Shukra Pharmaceuticals Company Announcements - News & Reports Screener

Screen SHUKRAPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 10, 2026.

The next most recent announcements are dated November 9, 2026 and November 4, 2026.

Date Update Actions
2026-11-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-09 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-04 Reg 32 -
2026-11-04 Unaudited Financial Results For The Quarter Ended 30Th September 2026 -
2026-11-04 Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30Th September 2026 -
2026-10-23 Update on board meeting -
2026-10-22 Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended September 2026 -
2026-10-12 Announcement under Regulation 30 (LODR)-Change of Company Name -
2026-10-10 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-06 Board Meeting Outcome for Allotment Of Shares Pursuant To Conversion Of Warrants -
2026-10-06 Clarification From The Company -
2026-10-06 Clarification sought from Shukra Pharmaceuticals Ltd -
2026-09-29 Voting Results With Scrutinizer Report -
2026-09-29 Voting Results And Scrutinizers Report -
2026-09-28 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-24 Closure of Trading Window -
2026-09-23 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-22 Corrigendum To Postal Ballot Notice -
2026-09-05 Reg. 34 (1) Annual Report. -
2026-09-05 AGM NOTICE -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹82.20, within a 52-week range of ₹41.42 to ₹82.25. The P/E ratio is 82.20 and the P/B ratio is 29.16, with earnings per unit of ₹0.50. Market capitalisation stands at ₹3,614.95 Cr and the dividend yield is 0.01%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 2 balance sheet periods, 8 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.